241 related articles for article (PubMed ID: 15280789)
1. Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma.
Martin-Carbonero L; Barrios A; Saballs P; Sirera G; Santos J; Palacios R; Valencia ME; Alegre M; Podzamczer D; González-Lahoz J;
AIDS; 2004 Aug; 18(12):1737-40. PubMed ID: 15280789
[TBL] [Abstract][Full Text] [Related]
2. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
Gbabe OF; Okwundu CI; Dedicoat M; Freeman EE
Cochrane Database Syst Rev; 2014 Aug; 8(8):CD003256. PubMed ID: 25221796
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe or progressive Kaposi's sarcoma in HIV-infected adults.
Gbabe OF; Okwundu CI; Dedicoat M; Freeman EE
Cochrane Database Syst Rev; 2014; (9):CD003256. PubMed ID: 25313415
[TBL] [Abstract][Full Text] [Related]
4. Treatment of HIV-1-associated Kaposi's sarcoma with pegylated liposomal doxorubicin and HAART simultaneously induces effective tumor remission and CD4+ T cell recovery.
Lichterfeld M; Qurishi N; Hoffmann C; Hochdorfer B; Brockmeyer NH; Arasteh K; Mauss S; Rockstroh JK;
Infection; 2005 Jun; 33(3):140-7. PubMed ID: 15940415
[TBL] [Abstract][Full Text] [Related]
5. Therapy of special HIV-associated diseases: HCV-HIV-co-infection and AIDS-related Kaposi's sarcoma - official satellite to the 7th European Conference on Clinical Aspects and Treatment of HIV-infection, October 23, 1999 in Lisbon, Portugal.
Goebel FD; Jablonowski H
Eur J Med Res; 1999 Dec; 4(12):507-13. PubMed ID: 10611054
[TBL] [Abstract][Full Text] [Related]
6. Timing of highly active antiretroviral therapy and chemotherapy for Kaposi's sarcoma in patients with HIV infection.
Loke WC; Spittle MF; Mitchell S; Kulasegaram R
Int J STD AIDS; 2006 Aug; 17(8):565-6. PubMed ID: 16925908
[TBL] [Abstract][Full Text] [Related]
7. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy.
Núñez M; Saballs P; Valencia ME; Santos J; Ferrer E; Santos I; Berrocal A; Galindo MJ; Podzamczer D; Gonzlez-Lahoz J;
HIV Clin Trials; 2001; 2(5):429-37. PubMed ID: 11673818
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of an HIV-positive patient with unmasking Kaposi's sarcoma immune reconstitution inflammatory syndrome.
Speicher DJ; Sehu MM; Johnson NW; Shaw DR
J Clin Virol; 2013 Jul; 57(3):282-5. PubMed ID: 23578530
[TBL] [Abstract][Full Text] [Related]
9. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
[TBL] [Abstract][Full Text] [Related]
10. The immunological effects of concomitant highly active antiretroviral therapy and liposomal anthracycline treatment of HIV-1-associated Kaposi's sarcoma.
Esdaile B; Davis M; Portsmouth S; Sarker D; Nelson M; Gazzard B; Bower M
AIDS; 2002 Nov; 16(17):2344-7. PubMed ID: 12441811
[TBL] [Abstract][Full Text] [Related]
11. Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma.
Coukell AJ; Spencer CM
Drugs; 1997 Mar; 53(3):520-38. PubMed ID: 9074848
[TBL] [Abstract][Full Text] [Related]
12. Treatment of Kaposi's sarcoma with liposomal doxorubicin.
Bergin C; O'Leary A; McCreary C; Sabra K; Mulcahy F
Am J Health Syst Pharm; 1995 Sep; 52(18):2001-4. PubMed ID: 8528867
[TBL] [Abstract][Full Text] [Related]
13. Regression of Kaposi's sarcoma lesions following highly active antiretroviral therapy in an HIV-infected patient.
Kumarasamy N; Venkatesh KK; Devaleenol B; Poongulali S; Ahilasamy N
Int J STD AIDS; 2008 Nov; 19(11):786-8. PubMed ID: 18931277
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo modulation of MDR1/P-glycoprotein in HIV-infected patients administered highly active antiretroviral therapy and liposomal doxorubicin.
Lucia MB; Rutella S; Leone G; Larocca LM; Vella S; Cauda R
J Acquir Immune Defic Syndr; 2002 Aug; 30(4):369-78. PubMed ID: 12138343
[TBL] [Abstract][Full Text] [Related]
15. Treatment of AIDS-related Kaposi's sarcoma with interleukin-12: rationale and preliminary evidence of clinical activity.
Yarchoan R; Pluda JM; Wyvill KM; Aleman K; Rodriguez-Chavez IR; Tosato G; Catanzaro AT; Steinberg SM; Little RF
Crit Rev Immunol; 2007; 27(5):401-14. PubMed ID: 18197804
[TBL] [Abstract][Full Text] [Related]
16. Long-term administration of pegylated liposomal doxorubicin at almost twice the recommended lifetime dose in 10 years without cardiotoxicity in a Japanese patient with HIV-associated Kaposi sarcoma.
Yokota K; Yotsumoto M; Muramatsu T; Saito M; Kamikubo Y; Ichiki A; Chikasawa Y; Bingo M; Hagiwara T; Amano K; Fukutake K
J Infect Chemother; 2020 Feb; 26(2):289-291. PubMed ID: 31537471
[TBL] [Abstract][Full Text] [Related]
17. Resolution of severe Kaposi's sarcoma after initiation of antiretroviral triple therapy.
Jung C; Bogner JR; Goebel F
Eur J Med Res; 1998 Sep; 3(9):439-42. PubMed ID: 9737891
[TBL] [Abstract][Full Text] [Related]
18. Use of liposomal anthracyclines in Kaposi's sarcoma.
Krown SE; Northfelt DW; Osoba D; Stewart JS
Semin Oncol; 2004 Dec; 31(6 Suppl 13):36-52. PubMed ID: 15717737
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for advanced human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy.
Cianfrocca M; Lee S; Von Roenn J; Tulpule A; Dezube BJ; Aboulafia DM; Ambinder RF; Lee JY; Krown SE; Sparano JA
Cancer; 2010 Aug; 116(16):3969-77. PubMed ID: 20564162
[TBL] [Abstract][Full Text] [Related]
20. Kaposi's sarcoma: Good outcome with doxorubicin, bleomycin and vincristine sulphate (ABV) chemotherapy and highly active antiretroviral therapy.
Hesseling PB; Katayi E; Wharin P; Bardin R; Kouya F; Palmer D; Glenn M; Kruger M
S Afr Med J; 2017 Oct; 107(11):952-953. PubMed ID: 29262935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]